GSK plc (GSK) on Tuesday said the China National Medical Products Administration (NMPA) has approved its shingles vaccine, Shingrix, for adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression.
Shingrix is the first and only shingles vaccine approved for this population in China.
The NMPA approval was supported by six clinical trials in adults, including patients who had recently undergone stem cell or kidney transplantation, or who have blood cancers, solid tumors, or HIV.
Shingrix is already approved for the prevention of shingles in people aged 50 and over in multiple countries and regions worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.